All Article Categories
At MSD Animal Health, many of us are veterinarians and dedicated pet owners who share a deep love for animals. Our mission is to ensure their health and well-being, which is why we emphasize the importance of providing accurate and balanced information about our products. One of our flagship products, Bravecto®, plays a crucial role in flea and tick prevention. Here’s why it matters and how we ensure its safety and efficacy.
The Importance of Flea and Tick Prevention
Fleas and ticks are more than just an inconvenience for pets—they pose significant health risks to both animals and humans. These parasites can transmit diseases such as Babesia (Biliary), Ehrlichia, and bartonellosis, among others. Effective prevention is essential to safeguard your pets and home from these harmful pests.
Bravecto® stands out as a leading solution in flea and tick control. It is the first and only treatment proven to kill fleas and multiple tick species for up to 12 weeks with a single dose. With over 13 million doses dispensed across 60 countries, Bravecto® has garnered widespread positive feedback from veterinarians and pet owners worldwide.
Extensive Safety Research
We take the safety of Bravecto® very seriously. Before its initial approval, Bravecto® underwent rigorous clinical research to establish its safety. Regulatory agencies worldwide have reviewed and approved Bravecto® based on this comprehensive research, confirming its safety when used according to the product label.
Global safety surveillance and extensive field studies reinforce the safety profile of Bravecto®. In controlled studies, Bravecto® has been used alongside other medications—such as vaccines, antibiotics, and steroids—without any adverse reactions. The most commonly reported issues are mild and transient gastrointestinal upsets, classified as rare. Importantly, our research does not show a causal relationship between Bravecto® and severe conditions like liver or kidney issues or cancer.
Commitment to Ethics and Transparency
As a responsible animal health company, MSD Animal Health is committed to transparency and ethical practices. We thoroughly investigate every report of a potential adverse event. Our team works closely with pet owners and veterinarians to gather detailed clinical information and determine whether our product might be involved.
It's crucial to distinguish between scientifically substantiated facts and anecdotal reports. A report of an adverse event does not automatically imply causation. We regularly report our findings to regulatory agencies to ensure a rigorous and science-based assessment of our products.
Your Partner in Pet Health
We are confident in the safety and efficacy of Bravecto® and are committed to providing accurate, evidence-based information for veterinarians and pet owners. Always consult with your veterinarian to make informed decisions about flea and tick control for your pets.
For more information about Bravecto®, visit www.bravecto.co.za.
Contact Us:
MSD Animal Health Companion Animal Technical Services and Pharmacovigilance Team
Tel: 011 923 9300
Email: [email protected]
References:
- Rohdich et al. Parasites & Vectors, 2014, 7: 83.
- Walther et al. Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs. Parasites & Vectors (2015) 8:508.
Bravecto® Reg. No. G4083 (Act 36/1947). Each chew contains 25 mg Fluralaner per kg body weight. Intervet South Africa (Pty) Ltd., Reg. No. 1991/006580/07